Lu C, Dong Y, Zhai Z, Gao T, Luo M, Feng T
BMJ Open. 2024; 14(12):e087645.
PMID: 39732483
PMC: 11683939.
DOI: 10.1136/bmjopen-2024-087645.
Neuropsychopharmacol Rep. 2024; 45(1):e12497.
PMID: 39587785
PMC: 11666347.
DOI: 10.1002/npr2.12497.
Citrome L, Suett M, Franzenburg K, Eshet R, Elgart A, Davis Rd G
Neuropsychiatr Dis Treat. 2024; 20:1901-1917.
PMID: 39399879
PMC: 11471067.
DOI: 10.2147/NDT.S459104.
Mlay J, Naidu T, Ramlall S, Mhlungu S, Zondi M, Lessells R
PLoS One. 2024; 19(8):e0309238.
PMID: 39172928
PMC: 11340960.
DOI: 10.1371/journal.pone.0309238.
Rivelli A, Fitzpatrick V, Nelson M, Laubmeier K, Zeni C, Mylavarapu S
Schizophrenia (Heidelb). 2024; 10(1):28.
PMID: 38424086
PMC: 10904733.
DOI: 10.1038/s41537-024-00448-2.
Perception of risk of relapse among patients with first episode and recurrent schizophrenia: a descriptive phenomenological study.
Yu H, Sun Y, Qin M, Ren J, Yu K, Song J
BMC Psychiatry. 2023; 23(1):582.
PMID: 37563579
PMC: 10413637.
DOI: 10.1186/s12888-023-05023-0.
Place of care and costs associated with acute episodes and remission in schizophrenia.
McIntyre R, Higa S, Doan Q, Amari D, Mercer D, Gillard P
J Manag Care Spec Pharm. 2023; 29(5):499-508.
PMID: 37121252
PMC: 10387981.
DOI: 10.18553/jmcp.2023.29.5.499.
Relapse prediction in schizophrenia with smartphone digital phenotyping during COVID-19: a prospective, three-site, two-country, longitudinal study.
Cohen A, Naslund J, Chang S, Nagendra S, Bhan A, Rozatkar A
Schizophrenia (Heidelb). 2023; 9(1):6.
PMID: 36707524
PMC: 9880926.
DOI: 10.1038/s41537-023-00332-5.
Three-year outcomes and predictors for full recovery in patients with early-stage psychosis.
Li L, Rami F, Lee B, Kim W, Kim S, Lee B
Schizophrenia (Heidelb). 2022; 8(1):87.
PMID: 36302861
PMC: 9613771.
DOI: 10.1038/s41537-022-00301-4.
Health care resource utilization and costs in patients receiving long-acting injectable vs oral antipsychotics: A comparative analysis from the Disease Recovery Evaluation and Modification (DREaM) study.
Basu A, Benson C, Turkoz I, Patel C, Baker P, Brown B
J Manag Care Spec Pharm. 2022; 28(10):1086-1095.
PMID: 36125055
PMC: 10373019.
DOI: 10.18553/jmcp.2022.28.10.1086.
Molecular Features Triggered by Antipsychotic Medication in Brain Cells.
Ramos-da-Silva L, Antunes A
Adv Exp Med Biol. 2022; 1400:65-73.
PMID: 35930226
DOI: 10.1007/978-3-030-97182-3_5.
Treatment Discontinuation Among Patients with Schizophrenia Treated with Brexpiprazole and Other Oral Atypical Antipsychotics in Japan: A Retrospective Observational Study.
Hishimoto A, Yasui-Furukori N, Sekine D, Matsukawa M, Yamada S
Adv Ther. 2022; 39(9):4299-4314.
PMID: 35904721
PMC: 9402511.
DOI: 10.1007/s12325-022-02252-9.
Long-Term Real-World Effectiveness of Aripiprazole Once-Monthly. Treatment Persistence and Its Correlates in the Italian and Spanish Clinical Practice: A Pooled Analysis.
Olivares J, Fagiolini A
Front Psychiatry. 2022; 13:877867.
PMID: 35573364
PMC: 9096029.
DOI: 10.3389/fpsyt.2022.877867.
Predicting Psychotic Relapse in Schizophrenia With Mobile Sensor Data: Routine Cluster Analysis.
Zhou J, Lamichhane B, Ben-Zeev D, Campbell A, Sano A
JMIR Mhealth Uhealth. 2022; 10(4):e31006.
PMID: 35404256
PMC: 9039818.
DOI: 10.2196/31006.
Real-world analysis of insurance churn among young adults with schizophrenia using the Colorado All-Payer Claims Database.
Pesa J, Rotter D, Papademetriou E, Potluri R, Patel C, Benson C
J Manag Care Spec Pharm. 2021; 28(1):26-38.
PMID: 34949116
PMC: 10372968.
DOI: 10.18553/jmcp.2022.28.1.26.
Predicting time to relapse in patients with schizophrenia according to patients' relapse history: a historical cohort study using real-world data in Sweden.
Jorgensen K, Bog M, Kabra M, Simonsen J, Adair M, Jonsson L
BMC Psychiatry. 2021; 21(1):634.
PMID: 34933680
PMC: 8690369.
DOI: 10.1186/s12888-021-03634-z.
Real-World Utilization Patterns of Long-Acting Injectable Antipsychotics in Canada: A Retrospective Study.
Agid O, Remington G, Fung C, Nightingale N, Duclos M, Anger G
Can J Psychiatry. 2021; 67(3):226-234.
PMID: 34792401
PMC: 8935594.
DOI: 10.1177/07067437211055413.
Associations Between Relapses and Psychosocial Outcomes in Patients With Schizophrenia in Real-World Settings in the United States.
Lin D, Joshi K, Keenan A, Shepherd J, Bailey H, Berry M
Front Psychiatry. 2021; 12:695672.
PMID: 34764891
PMC: 8576536.
DOI: 10.3389/fpsyt.2021.695672.
A longitudinal study of gene expression in first-episode schizophrenia; exploring relapse mechanisms by co-expression analysis in peripheral blood.
Gasso P, Rodriguez N, Martinez-Pinteno A, Mezquida G, Ribeiro M, Gonzalez-Penas J
Transl Psychiatry. 2021; 11(1):539.
PMID: 34667144
PMC: 8526619.
DOI: 10.1038/s41398-021-01645-8.
Clinical Pharmacy in Psychiatry: Towards Promoting Clinical Expertise in Psychopharmacology.
Javelot H, Faria C, Vandenberghe F, Dizet S, Langree B, Le Maout M
Pharmacy (Basel). 2021; 9(3).
PMID: 34449724
PMC: 8396352.
DOI: 10.3390/pharmacy9030146.